Follow
Joseph M Unger, PhD, MS
Title
Cited by
Cited by
Year
Underrepresentation of patients 65 years of age or older in cancer-treatment trials
LF Hutchins, JM Unger, JJ Crowley, CA Coltman Jr, KS Albain
New England Journal of Medicine 341 (27), 2061-2067, 1999
25461999
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy
HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, D Porter, PA Francis, ...
New England Journal of Medicine 372 (10), 923-932, 2015
6462015
The role of clinical trial participation in cancer research: barriers, evidence, and strategies
JM Unger, E Cook, E Tai, A Bleyer
American Society of Clinical Oncology Educational Book 36, 185-198, 2016
5322016
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group
KS Albain, JM Unger, JJ Crowley, CA Coltman, DL Hershman
JNCI: Journal of the National Cancer Institute 101 (14), 984-992, 2009
4932009
New treatment options have changed the survival of patients with follicular lymphoma
RI Fisher, M LeBlanc, OW Press, DG Maloney, JM Unger, TP Miller
Journal of Clinical Oncology 23 (33), 8447-8452, 2005
4792005
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma
PJ Stiff, JM Unger, JR Cook, LS Constine, S Couban, DA Stewart, ...
New England Journal of Medicine 369 (18), 1681-1690, 2013
469*2013
Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018
JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ...
JAMA oncology 5 (10), e191870-e191870, 2019
3972019
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other …
LM Rimsza, RA Roberts, TP Miller, JM Unger, M LeBlanc, RM Braziel, ...
Blood 103 (11), 4251-4258, 2004
3822004
Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation
JM Unger, R Vaidya, DL Hershman, LM Minasian, ME Fleury
JNCI: Journal of the National Cancer Institute 111 (3), 245-255, 2019
3762019
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study …
DO Persky, JM Unger, CM Spier, B Stea, M LeBlanc, MJ McCarty, ...
Journal of clinical oncology 26 (14), 2258-2263, 2008
3472008
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic …
M Lambertini, HCF Moore, RCF Leonard, S Loibl, P Munster, M Bruzzone, ...
Journal of clinical oncology 36 (19), 1981, 2018
3352018
Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer
DL Hershman, JM Unger, JD Wright, S Ramsey, C Till, CM Tangen, ...
JAMA oncology 2 (4), 453-461, 2016
304*2016
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of …
OW Press, JM Unger, RM Braziel, DG Maloney, TP Miller, M LeBlanc, ...
Journal of Clinical Oncology 24 (25), 4143-4149, 2006
2872006
Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial
DL Hershman, JM Unger, H Greenlee, JL Capodice, DL Lew, AK Darke, ...
Jama 320 (2), 167-176, 2018
2772018
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group
SH Bernstein, JM Unger, M LeBlanc, J Friedberg, TP Miller, RI Fisher
Journal of clinical oncology 27 (1), 114, 2009
2652009
Patient income level and cancer clinical trial participation
JM Unger, DL Hershman, KS Albain, CM Moinpour, JA Petersen, K Burg, ...
Journal of Clinical Oncology 31 (5), 536, 2013
2642013
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest …
VK Sondak, PY Liu, RJ Tuthill, RA Kempf, JM Unger, JA Sosman, ...
Journal of clinical oncology 20 (8), 2058-2066, 2002
2532002
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy
DL Hershman, JM Unger, KD Crew, LM Minasian, D Awad, CM Moinpour, ...
Journal of Clinical Oncology 31 (20), 2627, 2013
2412013
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome
JA Sosman, JM Unger, PY Liu, LE Flaherty, MS Park, RA Kempf, ...
Journal of Clinical Oncology 20 (8), 2067-2075, 2002
2322002
Comparison of survival outcomes among cancer patients treated in and out of clinical trials
JM Unger, WE Barlow, DP Martin, SD Ramsey, M LeBlanc, R Etzioni, ...
Journal of the National Cancer Institute 106 (3), dju002, 2014
2172014
The system can't perform the operation now. Try again later.
Articles 1–20